新規眼鏡レンズを用いた安全性と近視進行抑制の評価
The goal of this clinical trial is to test Novel spectacle lenses in myopic children. The main question it aims to answer are: safety and efficacy of the lenses. Participants will be asked to wear spectacles and participate in eye exams and questionnaires. Researchers will compare Novel spectacle lenses and general single vision spectacle lenses to see if the Novel spectacle lenses correct myopic ametropia, slow the progression of myopia and axial elongation.
調査の概要
状態
条件
詳細な説明
This is a 3-year prospective, multicenter, randomized, and single-masked*, parallel-group controlled clinical study. The purpose of this study is to evaluate the safety and efficacy of wearing Novel spectacle lenses to correct myopic ametropia, slow the progression of myopia and axial elongation in myopic children as compared to the use of single vision spectacles lenses.
The treatment arms are:
- Model A Novel spectacle lens
- Model B Novel spectacle lens
- Single vision spectacle lens
Single-masked:
The investigator responsible for conducting ocular data measurements related to the primary and secondary endpoints will be masked. The participants will not be informed the treatment arm during the clinical trial.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Beijing、中国
- Beijing Tongren Hospital, Capital Medical University
-
Guangzhou、中国
- Guangzhou Aier Eye Hospital
-
Shanghai、中国
- Eye and ENT Hospital of Fudan University
-
Shengyang、中国
- Shengyang He Eye Specialist Hospital
-
Tianjin、中国
- Tianjin Medical University Eye Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Participant and parent (or guardian) are able and willing to provide consent
- Participant and parent (or guardian) ensure to attend required study visits and adhere to participant requirements
- Parent or guardian understands and accepts random allocation of grouping, and that participant and parent (or guardian) will not be told which group participant is allocated to
- Participant willing to wear the study spectacles lens for a minimum of 12 hours per day for the duration of the study
- Age at time of parent or guardian consent and participant assent: 7 - 13 years old
- Spherical equivalent cycloplegic autorefraction: -1.00 to -7.00 D in each eye.
- Cycloplegic autorefraction astigmatism of 1.50 D or less in each eye
- Cycloplegic autorefraction anisometropia of 1.50 D or less
- Monocular best corrected distance visual acuity (BCDVA) equal to or better than logMAR 0.10 in each eye.
Exclusion Criteria:
- Participant is allergy to fluorescein, benoxinate, proparacaine, tropicamide or cyclopentolate eye drops
- Any ocular and systemic abnormalities might be expected to affect visual functions or refractive development
- (a) Have received treatment of myopic control pharmaceutical medication (e.g., atropine) or light fundus illuminance therapy (e.g., repeated red light therapy) within 6 months prior to entry into this study. (b) Have received treatment of myopia control such as contact lenses, orthokeratology lenses etc., progressive addition lenses, bifocal lenses, within 3 months. (c) Have received treatment of myopia control such as defocus spectacle lenses (difference between both eye's non-cycloplegic autorefraction and lens-meter results of the respective lenses are equal or less than 0.50 D SER) etc. within one month prior to entry into this study.
- Participant with clinically significant strabismus (including intermittent tropia)
- Medical history of binocular vision abnormalities
- Participant with amblyopia
- Participation in a clinical trial within 30 days prior to entry into this study or during participation
- Previous intraocular surgery
- Participant who, in the judgment of the Investigator, presence of any emotional, physiologic, or anatomical condition which may preclude participation in this study or provide an inappropriate landscape for the intended study treatment.
- Any medical treatment or medication which might have an influence on vision or interfere with study assessments
- Pathological myopia (myopia that leads to structural changes in the posterior segment of the eye including posterior staphyloma, myopic maculopathy, and high myopia-associated optic neuropathy)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:独身
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Model-A 斬新な眼鏡レンズ
|
Model-A Novel spectacle lenses will be given to 1 arm to wear for 36 months |
|
実験的:Model-B 斬新な眼鏡レンズ
|
Model-B Novel spectacle lenses will be given to 1 arm to wear for 36 months |
|
他の:単焦点眼鏡レンズ
|
Single Vision Spectacle lenses will be given to 1 arm to wear for 36 months |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Axial length
時間枠:24 months
|
The difference of Axial length changes over 24 months between treatment groups in low and moderate myopia (-1.00 D to -5.00 D) participants. |
24 months
|
|
Spherical equivalent cycloplegic autorefraction
時間枠:24 months
|
The difference of spherical equivalent cycloplegic autorefraction changes over 24 months between treatment groups in low and moderate myopia (-1.00 D to -5.00 D) participants |
24 months
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
軸方向の長さ
時間枠:36ヶ月
|
36ヶ月
|
|
球面等価の調節麻痺性自己屈折
時間枠:36ヶ月
|
36ヶ月
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。